In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicroPort Scientific Corp.

www.microport.com

Latest From MicroPort Scientific Corp.

2018 Global Approvals Analysis: Emerging-Market Regulators And Companies Make Their Presence Felt

The list of medical device approvals outside the US captured by Medtech Insight's Approvals Tracker in 2018 was shorter than in 2017, but it includes approvals from 14 different territories – more than one-fifth of the approvals came from emerging markets – covering more than 50 different indication categories.

Approvals Emerging Markets

Market Intel: Innovation Drives Growth, Draws Younger Patients In Joint Replacement Implants Market

The worldwide joint-replacement implants market is expected to hit $20bn by 2022, according to a new report from Meddevicetracker. The growth is driven by the rising number of elderly patients, whose natural joints have been damaged by arthritis, and the rising prevalence of chronic diseases, such as obesity and diabetes, and sport-related injuries. But a look at the market and the three largest segments  shoulder, knee and hip replacements  show that new technological advancements and improved surgical techniques are increasingly making joint replacement surgeries an option for younger people as well. Here's an overview and key insights from two orthopedic surgeons on the current market and key growth drivers and limiters.

Orthopedics Surgical Procedures

Terumo Dives Into China DES Market With Essen Springboard

Terumo is adding China to its existing global drug-eluting stent (DES) sales network, with the agreed acquisition of Beijing-based Essen Technology. This is a modest acquisition for the Japanese group but could give it a springboard into a potentially lucrative and important DES market.

Cardiovascular M & A

Endologix Looks To COO For New Leadership And Business Turnaround

Endovascular aortic repair specialist Endologix has promoted its COO John Onopchenko to the role of chief executive. He succeeds John McDermott, who stepped down as CEO in February following a couple of challenging years for the company.

Cardiology Appointments
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • MicroPort Medical Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • MicroPort Scientific Corp.
  • Senior Management
  • Chang ZhaoHua , PhD, CEO
    Hongbin Sun, CFO
    Qiyi Luo, CTO
  • Contact Info
  • MicroPort Scientific Corp.
    Phone: (86) 21 3895 4600
    ZhangJiang Hi-Tech Park
    501 Newton Rd.
    Shanghai, 201203
    China
UsernamePublicRestriction

Register